Item
1.01 Entry into a Material Definitive Agreement.
As
previously reported in a Current Report on From 8-K filed November 27, 2019, Generex Biotechnology Corporation (“Generex”
or the “Company”) entered into a definitive Stock Purchase Agreement (the “SPA”) for the purchase of 51%
of the outstanding capital stock (the “ALTuCELL Stock”) of GH Care, Inc. DBA ALTuCELL, Inc.(“ALTuCELL).
Under
the SPA, in exchange for the ALTuCELL Stock, Generex agreed to deliver at closing shares of Generex common stock and $2,500,000
in cash, less any cash advanced by Generex prior to closing. As of the date of this Report, Generex has advanced an aggregate
$112,000 to ALTuCELL.
In
addition to stock and cash at closing, Generex has agreed to pay up to an aggregate of $3,500,000 to ALTuCell upon ALTuCell’s
attainment of certain milestones.
Closing
of the transaction was anticipated to occur before the end of December, 2019, but has not occurred.
On
January 27, 2020, Generex and ALTuCell executed an Amendment Agreement to the SPA (the “Amendment”). Under the Amendment,
closing will occur within 30 days of the full execution of the Amendment, subject to the conditions to closing under the SPA.
The parties agreed that Generex will pay the $2.5 million closing payment from certain specifically identified sources.
If
the closing is not completed within 30 days of execution of the Amendment, SPA will lapse unless the parties agree in writing
to continue the transaction. Under the Amendment, Generex agreed to fund the ongoing operations of ALTuCELL during the extension
period with a payment of $100,000, to be paid within 2 business days of signing the Amendment.
If
ALTuCELL chooses to cancel the transaction as a result of delays due to forces beyond the
control
of Generex, including government regulatory delays or extended reviews by
regulators
that delay approvals of corporate actions, or by natural disasters or other
unforeseen
events beyond the control of Generex, ALTuCELL agrees to return all
payments
made by Generex.
This
Current Report contains a summary of the material terms of the Amendment. The summary of this document is subject to, and is qualified
in its entirety by, reference to the Amendment, which is filed as an exhibit hereto and incorporated herein by reference.
Forward-Looking
Statements
Statements
in this report may contain certain forward-looking statements. All statements included concerning activities, events or developments
that the Generex expects, believes or anticipates will or may occur in the future are forward-looking statements. Actual results
could differ materially from the results discussed in the forward-looking statements. Forward-looking statements are based on
current expectations and projections about future events and involve known and unknown risks, uncertainties and other factors
that may cause actual results and performance to be materially different from any future results or performance expressed or implied
by forward-looking statements. Known risks and uncertainties also include those identified from time to time in the reports filed
by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.
No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.
Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future
events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical
trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical
trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval
for any “phase” of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory
agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities
Litigation Reform Act. Additional information on these and other risks, uncertainties and factors is included in the Company’s
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed
with the SEC.